Peroxisome Proliferator-Activated Receptor- γ in Thyroid Autoimmunity

Area of Science:

• Endocrinology
• Immunology
• Ophthalmology

Background:

• Peroxisome proliferator-activated receptor-gamma (PPAR-γ) is expressed in thyroid and orbital tissues affected by autoimmune diseases like Graves' disease.
• Chemokines (C-X-C motif) ligand (CXCL)9, CXCL10, and CXCL11, mediated by (C-X-C motif) receptor 3 (CXCR3), are crucial in T helper 1 responses and thyroid autoimmune disorders.

Purpose of the Study:

• To investigate the therapeutic potential of PPAR-γ agonists in thyroid autoimmune disorders.
• To evaluate the inhibitory effects of PPAR-γ agonists on CXCR3 chemokines in relevant cell types.

Main Methods:

• In vitro studies assessing the impact of PPAR-γ agonists on thyrocytes and orbital fibroblasts, preadipocytes, and myoblasts from patients with Graves' ophthalmopathy (GO).
• Review of clinical data regarding the safety profiles of different PPAR-γ agonists, specifically rosiglitazone and pioglitazone.

Main Results:

• PPAR-γ agonists demonstrated a significant inhibitory effect on the expression and release of CXCR3 chemokines in various cell types.
• Pioglitazone exhibited a more favorable safety profile compared to rosiglitazone, which is associated with increased cardiovascular risks.

Conclusions:

• PPAR-γ agonists hold potential for treating thyroid autoimmune disorders by modulating inflammatory pathways.
• Pioglitazone is a potential candidate for further investigation in patients with thyroid autoimmunity due to its safety profile.